Sarepta

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne…
Read More...

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare…
Read More...